Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 771–780 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 771
- Medicine slug
- ioversol
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
0.26 L/kg
- Numeric value
- 0.26
- Unit
- L/kg
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:549d38db-d4ed-4708-8f76-7cdaa157063f (opens source in a new tab)
Ioversol label
Version not recorded · Effective date not recorded
The volume of distribution in adults was 0.26 L/kg body weight, consistent with distribution to the extracellular space.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6cb6ca5f-b249-49b0-a9eb-8aa583da7c74 (opens source in a new tab)
Ioversol label
Version not recorded · Effective date not recorded
The volume of distribution in adults was 0.26 L/kg body weight, consistent with distribution to the extracellular space.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd718d1c-f813-4114-a50d-c744ff7eb1bf (opens source in a new tab)
Ioversol label
Version not recorded · Effective date not recorded
The volume of distribution in adults was 0.26 L/kg body weight, consistent with distribution to the extracellular space.
Projected row 772
- Medicine slug
- irbesartan
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 45
- Source count
- 45
- Agreement rate
- 1
- Recorded readings
60%
- Numeric value
- 60
- Unit
- %
- Source records
- 45
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 45 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ab1ff46-d0b1-4762-9ebf-3e07dde8b048 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
There was no effect on serum uric acid during chronic oral administration, and no uricosuric effect. 12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:868bd0a7-38ff-4722-8063-a697af3be527 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7c093c2-3eef-4956-8a14-c36aada0304f (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddca7d7c-07fe-4df6-83ae-a9c05048b66e (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6eb0cb56-2e51-45ef-9fd5-5646cf9f78a3 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
There was no effect on serum uric acid during chronic oral administration, and no uricosuric effect. 12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0ec2ccc-7d79-4cde-a13e-08faeea4e934 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9644fa38-dd28-4888-9d55-80967c4fc8d7 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08c85ada-de6f-4cff-bc81-2332a22bef45 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f3408b4-44be-4a92-a59f-9b5a9716bc9a (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ecc490ea-a68e-4261-8be2-5020ac5ab803 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
There was no effect on serum uric acid during chronic oral administration, and no uricosuric effect. 12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfdf76ae-fedf-630c-e053-2995a90a9868 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
There was no effect on serum uric acid during chronic oral administration, and no uricosuric effect. 12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2113a901-2612-4557-b86d-3afc006fb8bb (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33416f1e-adee-4a45-b6fe-1fc39044e307 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6916c617-92d2-44f5-b968-6267517a2ce6 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
There was no effect on serum uric acid during chronic oral administration, and no uricosuric effect. 12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61ab1b6e-c849-49ca-a3f0-150774db649d (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
There was no effect on serum uric acid during chronic oral administration, and no uricosuric effect. 12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d80abcb-c995-82bc-e063-6294a90aa530 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
There was no effect on serum uric acid during chronic oral administration, and no uricosuric effect. 12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:950e33da-5e77-40df-b73b-dd084b36a804 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b587d89b-8ff9-4180-b31a-bbff5d365a1d (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
There was no effect on serum uric acid during chronic oral administration, and no uricosuric effect. 12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:029a90b6-0722-49be-8400-3ec29526aafd (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
There was no effect on serum uric acid during chronic oral administration, and no uricosuric effect. 12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b259fdd-ca4c-49c9-a50d-86066f5b0746 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efcd5f2e-1837-44ae-bc91-410c4d8b27c7 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
There was no effect on serum uric acid during chronic oral administration, and no uricosuric effect. 12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14d85774-2d74-4300-b4bb-c2836db4d5bd (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
There was no effect on serum uric acid during chronic oral administration, and no uricosuric effect. 12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44b72da1-4434-461f-8e3c-264ad46f85df (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c9bb449-6341-4f24-9d38-6ca952e07122 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:197871da-e0c5-49a9-8dd0-34a8c2685c6b (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21dd9a41-93c7-470c-94ed-f4c24e3d5633 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7885b2a8-be4e-48ab-8113-4e6ab791eb98 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fdf196d5-e933-49de-9c4c-bde50149c7d4 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83f5d5c8-27c0-4208-a291-0c4aa55a1ff5 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0898f423-0aa9-409c-8d4e-1349b59141d1 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8635a1c-ae06-4e23-99f7-e704f91d6f43 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c125c2a-a709-4cf1-b2d5-6e1d24a77377 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61b60f94-35e6-b90b-08ce-fbb2fe011f34 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Drug Interactions (See PRECAUTIONS : Drug Interactions .) Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f98fd95-e564-45b3-947f-45eba77f2af5 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e0ddb7b-80c5-47ab-afee-c74bb735e829 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c1fc197-c2d9-453c-b79f-b53de89c188b (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70a25c6d-23ce-488c-9ef8-62b3b99e5052 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
There was no effect on serum uric acid during chronic oral administration, and no uricosuric effect. 12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc07bbf5-b1c6-4854-b6af-e06520c20728 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:068224c4-a34d-32d7-bb2a-7eed44ccf7d3 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
There was no effect on serum uric acid during chronic oral administration, and no uricosuric effect. 12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9adacfa2-2814-4deb-9e34-c3b3c8dcd41a (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
There was no effect on serum uric acid during chronic oral administration, and no uricosuric effect. 12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6babdb48-8384-49ce-a759-d380d79a4010 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
There was no effect on serum uric acid during chronic oral administration, and no uricosuric effect. 12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ada35ec2-8472-411a-8e7c-ff1a0df94ab5 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed789dc1-0b39-4efc-990d-7b6b43a8b3ba (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb58acb0-2dc0-45ee-86bb-b405b1b75cff (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b8581c1-d052-4fe2-a9fc-cf7adf0f9061 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%.
Projected row 773
- Medicine slug
- irbesartan
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 45
- Source count
- 45
- Agreement rate
- 0.977778
- Recorded readings
11 to 15 hours
- Numeric value
- 11
- Unit
- hours
- Source records
- 44
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 44 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ab1ff46-d0b1-4762-9ebf-3e07dde8b048 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:868bd0a7-38ff-4722-8063-a697af3be527 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7c093c2-3eef-4956-8a14-c36aada0304f (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6eb0cb56-2e51-45ef-9fd5-5646cf9f78a3 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0ec2ccc-7d79-4cde-a13e-08faeea4e934 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9644fa38-dd28-4888-9d55-80967c4fc8d7 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08c85ada-de6f-4cff-bc81-2332a22bef45 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f3408b4-44be-4a92-a59f-9b5a9716bc9a (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ecc490ea-a68e-4261-8be2-5020ac5ab803 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfdf76ae-fedf-630c-e053-2995a90a9868 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2113a901-2612-4557-b86d-3afc006fb8bb (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33416f1e-adee-4a45-b6fe-1fc39044e307 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6916c617-92d2-44f5-b968-6267517a2ce6 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61ab1b6e-c849-49ca-a3f0-150774db649d (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d80abcb-c995-82bc-e063-6294a90aa530 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:950e33da-5e77-40df-b73b-dd084b36a804 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b587d89b-8ff9-4180-b31a-bbff5d365a1d (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:029a90b6-0722-49be-8400-3ec29526aafd (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b259fdd-ca4c-49c9-a50d-86066f5b0746 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efcd5f2e-1837-44ae-bc91-410c4d8b27c7 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14d85774-2d74-4300-b4bb-c2836db4d5bd (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44b72da1-4434-461f-8e3c-264ad46f85df (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c9bb449-6341-4f24-9d38-6ca952e07122 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:197871da-e0c5-49a9-8dd0-34a8c2685c6b (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21dd9a41-93c7-470c-94ed-f4c24e3d5633 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7885b2a8-be4e-48ab-8113-4e6ab791eb98 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fdf196d5-e933-49de-9c4c-bde50149c7d4 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83f5d5c8-27c0-4208-a291-0c4aa55a1ff5 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0898f423-0aa9-409c-8d4e-1349b59141d1 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8635a1c-ae06-4e23-99f7-e704f91d6f43 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c125c2a-a709-4cf1-b2d5-6e1d24a77377 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61b60f94-35e6-b90b-08ce-fbb2fe011f34 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f98fd95-e564-45b3-947f-45eba77f2af5 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e0ddb7b-80c5-47ab-afee-c74bb735e829 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c1fc197-c2d9-453c-b79f-b53de89c188b (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70a25c6d-23ce-488c-9ef8-62b3b99e5052 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc07bbf5-b1c6-4854-b6af-e06520c20728 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:068224c4-a34d-32d7-bb2a-7eed44ccf7d3 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9adacfa2-2814-4deb-9e34-c3b3c8dcd41a (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6babdb48-8384-49ce-a759-d380d79a4010 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ada35ec2-8472-411a-8e7c-ff1a0df94ab5 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed789dc1-0b39-4efc-990d-7b6b43a8b3ba (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb58acb0-2dc0-45ee-86bb-b405b1b75cff (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b8581c1-d052-4fe2-a9fc-cf7adf0f9061 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 to 15 hours.
11 hours
- Numeric value
- 11
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddca7d7c-07fe-4df6-83ae-a9c05048b66e (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The terminal elimination half-life of irbesartan averages 11 hours to 15 hours.
Projected row 774
- Medicine slug
- irbesartan
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 45
- Source count
- 45
- Agreement rate
- 0.977778
- Recorded readings
1.5 to 2 hours
- Numeric value
- 1.5
- Unit
- hours
- Source records
- 44
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 44 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ab1ff46-d0b1-4762-9ebf-3e07dde8b048 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan tablets, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:868bd0a7-38ff-4722-8063-a697af3be527 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartran, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7c093c2-3eef-4956-8a14-c36aada0304f (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6eb0cb56-2e51-45ef-9fd5-5646cf9f78a3 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan tablets, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0ec2ccc-7d79-4cde-a13e-08faeea4e934 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan tablets, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9644fa38-dd28-4888-9d55-80967c4fc8d7 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartran, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08c85ada-de6f-4cff-bc81-2332a22bef45 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan tablets, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f3408b4-44be-4a92-a59f-9b5a9716bc9a (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ecc490ea-a68e-4261-8be2-5020ac5ab803 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan tablets, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfdf76ae-fedf-630c-e053-2995a90a9868 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartran, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2113a901-2612-4557-b86d-3afc006fb8bb (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33416f1e-adee-4a45-b6fe-1fc39044e307 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6916c617-92d2-44f5-b968-6267517a2ce6 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan tablets, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61ab1b6e-c849-49ca-a3f0-150774db649d (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d80abcb-c995-82bc-e063-6294a90aa530 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:950e33da-5e77-40df-b73b-dd084b36a804 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartran, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b587d89b-8ff9-4180-b31a-bbff5d365a1d (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan tablets, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:029a90b6-0722-49be-8400-3ec29526aafd (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan tablets, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b259fdd-ca4c-49c9-a50d-86066f5b0746 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efcd5f2e-1837-44ae-bc91-410c4d8b27c7 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan tablets, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14d85774-2d74-4300-b4bb-c2836db4d5bd (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan tablets, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44b72da1-4434-461f-8e3c-264ad46f85df (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan tablets, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c9bb449-6341-4f24-9d38-6ca952e07122 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:197871da-e0c5-49a9-8dd0-34a8c2685c6b (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartran, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21dd9a41-93c7-470c-94ed-f4c24e3d5633 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartran, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7885b2a8-be4e-48ab-8113-4e6ab791eb98 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of AVAPRO, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fdf196d5-e933-49de-9c4c-bde50149c7d4 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83f5d5c8-27c0-4208-a291-0c4aa55a1ff5 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan tablets, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0898f423-0aa9-409c-8d4e-1349b59141d1 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of Irbesartan Tablets, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8635a1c-ae06-4e23-99f7-e704f91d6f43 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan tablets, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c125c2a-a709-4cf1-b2d5-6e1d24a77377 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartran, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61b60f94-35e6-b90b-08ce-fbb2fe011f34 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartran, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f98fd95-e564-45b3-947f-45eba77f2af5 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e0ddb7b-80c5-47ab-afee-c74bb735e829 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartran, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c1fc197-c2d9-453c-b79f-b53de89c188b (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70a25c6d-23ce-488c-9ef8-62b3b99e5052 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan tablets, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc07bbf5-b1c6-4854-b6af-e06520c20728 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan tablets, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:068224c4-a34d-32d7-bb2a-7eed44ccf7d3 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9adacfa2-2814-4deb-9e34-c3b3c8dcd41a (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan tablets, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6babdb48-8384-49ce-a759-d380d79a4010 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan tablets, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ada35ec2-8472-411a-8e7c-ff1a0df94ab5 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan tablets, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed789dc1-0b39-4efc-990d-7b6b43a8b3ba (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan tablets, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb58acb0-2dc0-45ee-86bb-b405b1b75cff (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b8581c1-d052-4fe2-a9fc-cf7adf0f9061 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartran, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing.
1.5 hours
- Numeric value
- 1.5
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddca7d7c-07fe-4df6-83ae-a9c05048b66e (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
Following oral administration of irbesartan, peak plasma concentrations of irbesartan are attained at 1.5 hours to 2 hours after dosing.
Projected row 775
- Medicine slug
- irbesartan
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 45
- Source count
- 45
- Agreement rate
- 0.977778
- Recorded readings
53 to 93 liters
- Numeric value
- 53
- Unit
- L
- Source records
- 44
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 44 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ab1ff46-d0b1-4762-9ebf-3e07dde8b048 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:868bd0a7-38ff-4722-8063-a697af3be527 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7c093c2-3eef-4956-8a14-c36aada0304f (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6eb0cb56-2e51-45ef-9fd5-5646cf9f78a3 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0ec2ccc-7d79-4cde-a13e-08faeea4e934 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9644fa38-dd28-4888-9d55-80967c4fc8d7 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08c85ada-de6f-4cff-bc81-2332a22bef45 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f3408b4-44be-4a92-a59f-9b5a9716bc9a (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ecc490ea-a68e-4261-8be2-5020ac5ab803 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfdf76ae-fedf-630c-e053-2995a90a9868 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2113a901-2612-4557-b86d-3afc006fb8bb (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33416f1e-adee-4a45-b6fe-1fc39044e307 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6916c617-92d2-44f5-b968-6267517a2ce6 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61ab1b6e-c849-49ca-a3f0-150774db649d (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d80abcb-c995-82bc-e063-6294a90aa530 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:950e33da-5e77-40df-b73b-dd084b36a804 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b587d89b-8ff9-4180-b31a-bbff5d365a1d (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:029a90b6-0722-49be-8400-3ec29526aafd (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b259fdd-ca4c-49c9-a50d-86066f5b0746 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efcd5f2e-1837-44ae-bc91-410c4d8b27c7 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14d85774-2d74-4300-b4bb-c2836db4d5bd (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44b72da1-4434-461f-8e3c-264ad46f85df (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c9bb449-6341-4f24-9d38-6ca952e07122 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:197871da-e0c5-49a9-8dd0-34a8c2685c6b (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21dd9a41-93c7-470c-94ed-f4c24e3d5633 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7885b2a8-be4e-48ab-8113-4e6ab791eb98 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fdf196d5-e933-49de-9c4c-bde50149c7d4 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:83f5d5c8-27c0-4208-a291-0c4aa55a1ff5 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0898f423-0aa9-409c-8d4e-1349b59141d1 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8635a1c-ae06-4e23-99f7-e704f91d6f43 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c125c2a-a709-4cf1-b2d5-6e1d24a77377 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61b60f94-35e6-b90b-08ce-fbb2fe011f34 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f98fd95-e564-45b3-947f-45eba77f2af5 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e0ddb7b-80c5-47ab-afee-c74bb735e829 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c1fc197-c2d9-453c-b79f-b53de89c188b (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70a25c6d-23ce-488c-9ef8-62b3b99e5052 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc07bbf5-b1c6-4854-b6af-e06520c20728 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:068224c4-a34d-32d7-bb2a-7eed44ccf7d3 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9adacfa2-2814-4deb-9e34-c3b3c8dcd41a (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6babdb48-8384-49ce-a759-d380d79a4010 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ada35ec2-8472-411a-8e7c-ff1a0df94ab5 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed789dc1-0b39-4efc-990d-7b6b43a8b3ba (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb58acb0-2dc0-45ee-86bb-b405b1b75cff (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b8581c1-d052-4fe2-a9fc-cf7adf0f9061 (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 to 93 liters.
53 liters
- Numeric value
- 53
- Unit
- L
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddca7d7c-07fe-4df6-83ae-a9c05048b66e (opens source in a new tab)
Irbesartan label
Version not recorded · Effective date not recorded
The average volume of distribution is 53 liters to 93 liters.
Projected row 776
- Medicine slug
- irinotecan
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 16
- Source count
- 15
- Agreement rate
- 1
- Recorded readings
6 to 12 hours
- Numeric value
- 6
- Unit
- hours
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d04f2471-3085-4fc8-a657-bb3918d48e6e (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c6aa884-750e-4b11-9955-bc7ab6e9c2ad (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85ed6019-f462-4abe-a89e-ad991623c86d (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c527c2e-9062-4afe-dbbb-f650db3a340f (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8fe98987-e526-4729-a8f4-c7230f424108 (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee45f127-8450-4455-a945-a1f5707f1d39 (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de634e80-328a-4473-b395-0172683a2411 (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b26e5d27-dba5-7538-9e7b-48b358998cbb (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e518dfc6-7e93-4fee-a66c-51e1ab71c056 (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e1fdcaa-918f-4cd8-9c7a-4c538d866198 (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
Administration of irinotecan has resulted in antitumor activity in mice bearing cancers of rodent origin and in human carcinoma xenografts of various histological types. 12.3 Pharmacokinetics After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afcdde49-ec0c-4c56-a1af-2917185b1a08 (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f98e9ed-f7b1-5346-af72-fccb0abf3f4b (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a30d551-9ea7-47ea-9073-f541bff457a3 (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be716692-6b4f-47b6-83d1-01665861626b (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:caab50e6-0dad-4ddd-9a6c-96cc2b87aee7 (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours.
Projected row 777
- Medicine slug
- irinotecan
- Compared field
- proteinBinding
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 16
- Source count
- 16
- Agreement rate
- 0.875
- Recorded readings
30%
- Numeric value
- 30
- Unit
- %
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d04f2471-3085-4fc8-a657-bb3918d48e6e (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
5 13.3±6.01 26.3±11.9 229±108 10.4 a ±3.1 340 (N=6) 3,392 ±874 20,604 ±6,027 11.7 b ±1.0 234 ±69.6 13.9 ±4.0 56.0 ±28.2 474 ±245 21.0 b ±4.3 Distribution Irinotecan exhibits moderate plasma protein binding (30% to 68% bound).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c6aa884-750e-4b11-9955-bc7ab6e9c2ad (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
nute infusion t 1/2 - Terminal elimination half-life Vz - Volume of distribution of terminal elimination phase CL - Total systemic clearance Distribution Irinotecan exhibits moderate plasma protein binding (30% to 68% bound).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85ed6019-f462-4abe-a89e-ad991623c86d (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
3 ±6.01 26.3 ±11.9 229 ±108 10.4 a ±3.1 340 (N = 6) 3,392 ±874 20,604 ±6,027 11.7 b ±1.0 234 ±69.6 13.9 ±4.0 56.0 ±28.2 474 ±245 21.0 b ±4.3 Distribution Irinotecan exhibits moderate plasma protein binding (30% to 68% bound).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c527c2e-9062-4afe-dbbb-f650db3a340f (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
Because of the longer collection period, these values provide a more accurate reflection of the terminal elimination half-lives of irinotecan and SN-38. ±1.0 234 ±69.6 13.9 ±4.0 56.0 ±28.2 474 ±245 21.0 ±4.3 Distribution Irinotecan exhibits moderate plasma protein binding (30% to 68% bound).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8fe98987-e526-4729-a8f4-c7230f424108 (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
3 ±6.01 26.3 ±11.9 229 ±108 10.4 a ±3.1 340 (N = 6) 3,392 ±874 20,604 ±6,027 11.7 b ±1.0 234 ±69.6 13.9 ±4.0 56.0 ±28.2 474 ±245 21.0 b ±4.3 Distribution Irinotecan exhibits moderate plasma protein binding (30% to 68% bound).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee45f127-8450-4455-a945-a1f5707f1d39 (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
±3,270 ±0.7 ±48.5 ±6.01 ±11.9 ±108 ±3.1 340 3,392 20,604 1 l.7 b 234 13.9 56.0 474 21.0 b (N=6) ±874 ±6,027 ±1.0 ±69.6 ±4.0 ±28.2 ±245 ±4.3 Distribution Irinotecan exhibits moderate plasma protein binding (30% to 68% bound).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de634e80-328a-4473-b395-0172683a2411 (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
Distribution Irinotecan exhibits moderate plasma protein binding (30% to 68% bound).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b26e5d27-dba5-7538-9e7b-48b358998cbb (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
Distribution Irinotecan exhibits moderate plasma protein binding (30% to 68% bound).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e518dfc6-7e93-4fee-a66c-51e1ab71c056 (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
Because of the longer collection period, these values provide a more accurate reflection of the terminal elimination half-lives of irinotecan and SN-38. ±1.0 234 ±69.6 13.9 ±4.0 56.0 ±28.2 474 ±245 21.0 ±4.3 Distribution Irinotecan exhibits moderate plasma protein binding (30% to 68% bound).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afcdde49-ec0c-4c56-a1af-2917185b1a08 (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
3 ±6.01 26.3 ±11.9 229 ±108 10.4 a ±3.1 340 (N = 6) 3,392 ±874 20,604 ±6,027 11.7 b ±1.0 234 ±69.6 13.9 ±4.0 56.0 ±28.2 474 ±245 21.0 b ±4.3 Distribution Irinotecan exhibits moderate plasma protein binding (30% to 68% bound).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f98e9ed-f7b1-5346-af72-fccb0abf3f4b (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
Distribution Irinotecan exhibits moderate plasma protein binding (30% to 68% bound).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a30d551-9ea7-47ea-9073-f541bff457a3 (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
6.3 ± 11.9 229 ± 108 10.4 a ± 3.1 340 (N=6) 3,392 ± 874 20,604 ± 6,027 11.7 b ± 1.0 234 ± 69.6 13.9 ± 4.0 56.0 ± 28.2 474 ± 245 21.0 b ± 4.3 Distribution Irinotecan exhibits moderate plasma protein binding (30% to 68% bound).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be716692-6b4f-47b6-83d1-01665861626b (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
nute infusion t 1/2 - Terminal elimination half-life Vz - Volume of distribution of terminal elimination phase CL - Total systemic clearance Distribution Irinotecan exhibits moderate plasma protein binding (30% to 68% bound).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:caab50e6-0dad-4ddd-9a6c-96cc2b87aee7 (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
3.3 ±6.01 26.3 ±11.9 229 ±108 10.4 a ±3.1 340 (N=6) 3,392 ±874 20,604 ±6,027 11.7 b ±1.0 234 ±69.6 13.9 ±4.0 56.0 ±28.2 474 ±245 21.0 b ±4.3 Distribution Irinotecan exhibits moderate plasma protein binding (30% to 68% bound).
0.44%
- Numeric value
- 0.44
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8b58efa-1820-48a4-b70d-62918fc4abfc (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
Plasma protein binding is <0.44% of the total irinotecan in ONIVYDE.
50%
- Numeric value
- 50
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e1fdcaa-918f-4cd8-9c7a-4c538d866198 (opens source in a new tab)
Irinotecan label
Version not recorded · Effective date not recorded
In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold; however, the plasma area under the concentration versus time curve (AUC) values for SN-38 are 2% to 8% of irinotecan and SN-38 is 95% bound to plasma proteins compared to approximately 50% bound to plasma proteins for irinotecan [see Clinical Pharmacology (12.3) ] .
Projected row 778
- Medicine slug
- iron-dextran
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
5 hours
- Numeric value
- 5
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99bf34be-cb8a-46d1-9637-5544dc2da287 (opens source in a new tab)
Iron Dextran label
Version not recorded · Effective date not recorded
Various studies involving intravenously administered 59 Fe iron dextran to iron deficient subjects, some of whom had coexisting disease, have yielded half-life values ranging from 5 hours to more than 20 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a4cd424-865d-fdd1-e053-2995a90a00ff (opens source in a new tab)
Iron Dextran label
Version not recorded · Effective date not recorded
Various studies involving intravenously administered 59Fe iron dextran to iron deficient subjects, some of whom had coexisting diseases, have yielded half-life values ranging from 5 hours to more than 20 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94b01b1e-794b-4bea-8e24-2e54683fc023 (opens source in a new tab)
Iron Dextran label
Version not recorded · Effective date not recorded
Various studies involving intravenously administered 59 Fe iron dextran to iron deficient subjects, some of whom had coexisting disease, have yielded half-life values ranging from 5 hours to more than 20 hours.
Projected row 779
- Medicine slug
- iron-sucrose
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 6
- Source count
- 6
- Agreement rate
- 1
- Recorded readings
6 h
- Numeric value
- 6
- Unit
- hours
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78c04f10-0489-4e45-8cb5-28a6789d1149 (opens source in a new tab)
Iron Sucrose label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics In healthy adults administered intravenous doses of iron sucrose, its iron component exhibited first order kinetics with an elimination half-life of 6 h, total clearance of 1.2 L/h, and steady state apparent volume of distribution of 7.9 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f19c80e-22e9-4bab-aa53-4d2d958119ed (opens source in a new tab)
Iron Sucrose label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics In healthy adults administered intravenous doses of Iron Sucrose Injection, its iron component exhibited first order kinetics with an elimination half-life of 6 h, total clearance of 1.2 L/h, and steady state apparent volume of distribution of 7.9 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:626dc9e5-c6b4-4f9c-9bf4-774fd3ae619a (opens source in a new tab)
Iron Sucrose label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics In healthy adults administered intravenous doses of Venofer, its iron component exhibited first order kinetics with an elimination half-life of 6 h, total clearance of 1.2 L/h, and steady state apparent volume of distribution of 7.9 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1ab1a22-2b99-4d27-8b5a-9c3bcd5e3040 (opens source in a new tab)
Iron Sucrose label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics In healthy adults administered intravenous doses of Venofer, its iron component exhibited first order kinetics with an elimination half-life of 6 h, total clearance of 1.2 L/h, and steady state apparent volume of distribution of 7.9 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f109bdb-a412-43b2-84c7-9dad05e85a71 (opens source in a new tab)
Iron Sucrose label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics In healthy adults administered intravenous doses of iron sucrose, its iron component exhibited first order kinetics with an elimination half-life of 6 h, total clearance of 1.2 L/h, and steady state apparent volume of distribution of 7.9 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b998ef36-81fa-40a1-9cd1-6d6156f91564 (opens source in a new tab)
Iron Sucrose label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics In healthy adults administered intravenous doses of Venofer, its iron component exhibited first order kinetics with an elimination half-life of 6 h, total clearance of 1.2 L/h, and steady state apparent volume of distribution of 7.9 L.
Projected row 780
- Medicine slug
- iron-sucrose
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 6
- Source count
- 6
- Agreement rate
- 1
- Recorded readings
7.9 L
- Numeric value
- 7.9
- Unit
- L
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78c04f10-0489-4e45-8cb5-28a6789d1149 (opens source in a new tab)
Iron Sucrose label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics In healthy adults administered intravenous doses of iron sucrose, its iron component exhibited first order kinetics with an elimination half-life of 6 h, total clearance of 1.2 L/h, and steady state apparent volume of distribution of 7.9 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f19c80e-22e9-4bab-aa53-4d2d958119ed (opens source in a new tab)
Iron Sucrose label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics In healthy adults administered intravenous doses of Iron Sucrose Injection, its iron component exhibited first order kinetics with an elimination half-life of 6 h, total clearance of 1.2 L/h, and steady state apparent volume of distribution of 7.9 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:626dc9e5-c6b4-4f9c-9bf4-774fd3ae619a (opens source in a new tab)
Iron Sucrose label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics In healthy adults administered intravenous doses of Venofer, its iron component exhibited first order kinetics with an elimination half-life of 6 h, total clearance of 1.2 L/h, and steady state apparent volume of distribution of 7.9 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1ab1a22-2b99-4d27-8b5a-9c3bcd5e3040 (opens source in a new tab)
Iron Sucrose label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics In healthy adults administered intravenous doses of Venofer, its iron component exhibited first order kinetics with an elimination half-life of 6 h, total clearance of 1.2 L/h, and steady state apparent volume of distribution of 7.9 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f109bdb-a412-43b2-84c7-9dad05e85a71 (opens source in a new tab)
Iron Sucrose label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics In healthy adults administered intravenous doses of iron sucrose, its iron component exhibited first order kinetics with an elimination half-life of 6 h, total clearance of 1.2 L/h, and steady state apparent volume of distribution of 7.9 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b998ef36-81fa-40a1-9cd1-6d6156f91564 (opens source in a new tab)
Iron Sucrose label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics In healthy adults administered intravenous doses of Venofer, its iron component exhibited first order kinetics with an elimination half-life of 6 h, total clearance of 1.2 L/h, and steady state apparent volume of distribution of 7.9 L.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=770Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.